AGYTF
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.00 | $36M | -$15M |
| 2025 Q4 | -0.01 | $30M | -$23M |
| 2024 Q2 | -0.00 | $34M | -$9M |
| 2024 Q4 | -0.01 | $22M | -$23M |
| 2023 Q2 | -0.01 | $34M | -$13M |
| 2023 Q4 | -0.03 | $20M | -$25M |
| 2022 Q2 | -0.01 | $40M | -$10M |
| 2022 Q4 | -0.03 | $24M | -$20M |